Genedata Screener 6.0 Expands into Time Series Data Analysis with New Kinetics Analyzer Module

Basel, Switzerland, September 22, 2008

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Screener® 6.0, the latest version of its open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS) analysis. Screener 6.0 combines an enterprise-wide assay data management platform with high-performance processing workflows and flexible analysis tools and has a special focus on time series data analysis.

Time series data is complex with hundreds of values per well. Sensible data aggregation is needed to derive meaningful results from such time-dependent responses. The latest Screener release includes an enhanced solution to these kinetics assay data management challenges. This new functionality enables users to rapidly analyze, integrate and manage extensive sets of time series data, independent of instrumentation, technology, volume or location.

In the Kinetics Analyzer module users can optimize aggregation rules, re-analyze data for complete campaigns and systematically gather mechanistic information from curve shape in addition to amplitude. The application programming interfaces (APIs) included in this open system can be easily connected to the many different readers already on the market, as well as implemented to provide custom aggregation functions for specific experiments. Quality assessment and visualization are vastly improved and interferences with biological response can be identified from kinetics traces. With consistent data management and visualization, the resulting parameters are optimized for each assay and users are able to extract more information to get better results and better qualified hits from each single experiment.

“Genedata Screener is already licensed by the top pharmaceutical, agrochemical and life science biotech companies worldwide,” said Dr. Othmar Pfannes, CEO of Genedata. “With the addition of the Kinetics Analyzer module, Screener 6.0 extends the use of our enterprise high throughput and high content screening platform to the rapidly growing market of time series data analysis. More than ever before research groups spanning the globe can easily analyze, manage and share complex data regardless of the instrumentation they use.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

Contact
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.